- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07246902
Mobilisering och utfall efter venstängning (MOVE)
MOVE - Mobilisering och utfall efter venös stängning - Ett prospektivt register över verkliga världens utfall/användning/bevis för MYNX CONTROL™ VENOUS vaskulär stängningsanordning 6F-12F
The primary objective of this post-market registry is to collect real-world outcomes and evaluate usage practice of MYNX CONTROL™ VENOUS (MCV) Vascular Closure Device (VCD) 6F-12F in sealing femoral venous access sites in patients who have undergone endovascular procedures in a real-world setting.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The study is a single-arm, prospective, multi-center, observational, real-world registry of venous access site closures utilizing MYNX CONTROL™ VENOUS VCD 6F-12F following endovascular procedures. The study will enroll approximately 300 subjects in approximately 15 study sites in the United States.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
California
-
Los Angeles, California, Förenta staterna, 90048
- Cedars Sinai Medical Center
-
Palo Alto, California, Förenta staterna, 94304
- Stanford University School of Medicine
-
-
Colorado
-
Littleton, Colorado, Förenta staterna, 80210
- South Denver Cardiology
-
-
Florida
-
Orlando, Florida, Förenta staterna, 32803
- AdventHealth Orlando
-
-
Illinois
-
Glenview, Illinois, Förenta staterna, 60026
- Glenbrook Hospital
-
-
Kansas
-
Overland Park, Kansas, Förenta staterna, 66211
- KC Heart and Rhythm Institute
-
-
Kentucky
-
Lexington, Kentucky, Förenta staterna, 40503
- Baptist Health Lexington
-
-
North Carolina
-
Raleigh, North Carolina, Förenta staterna, 27607
- North Carolina Heart & Vascular Research, LLC
-
-
Washington
-
Bellevue, Washington, Förenta staterna, 98004
- Overlake Medical Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
The study includes patients who undergo catheter-based procedures utilizing 6F to 12F inner diameter procedural sheaths, with single or multiple venous access sites in one or both limbs, and have their venous access site(s) closed with MYNX CONTROL™ VENOUS VCD 6F-12F per IFU.
Beskrivning
Inclusion Criteria
- Able and willing to provide informed consent and to complete a follow-up visit at 14 ± 7 days post-procedure.
- Individuals undergoing catheter-based procedures utilizing 6F to 12F inner diameter procedural sheaths, with single or multiple venous access sites in one or both limbs.
- Individuals who are candidates to have their venous access site(s) closed with MYNX CONTROL™ VENOUS VCD 6F-12F per IFU.
- At the time of enrollment, the Investigator deems the subject a candidate for same-day discharge (SDD) per standard of care (no procedure related events/complications e.g., no new pericardial effusion, post-procedure diuresis not needed, etc.).
Exclusion Criteria
- Presence of bruit, palpable aneurysm, significant candida or groin infection.
- Prior to closure, presence of hematoma in the accessed limb.
- Currently involved in any other clinical trial that may interfere with the outcomes of this study as determined by the Investigator.
- Planned use of other closure devices or techniques other than MYNX CONTROL™ VENOUS VCD 6F-12F.
- Life expectancy <12 months.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
MCV VCD Treatment
Subjects who undergo catheter-based procedures utilizing 6F to 12F inner diameter procedural sheaths, with single or multiple venous access sites in one or both limbs, and have their venous access site(s) closed with MYNX CONTROL™ VENOUS VCD 6F-12F per IFU. |
The MYNX CONTROLTM VENOUS (MCV) Vascular Closure Device (VCD) 6F-12F is indicated for use to seal femoral venous access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing 6F to 12F procedural sheaths, with single or multiple access sites in one or both limbs. MCV VCD is designed to achieve femoral vein hemostasis via delivery of the GRIP TECHNOLOGY™ sealant (an extravascular, water-soluble synthetic hydrogel), using a balloon catheter in conjunction with a standard procedural sheath. The sealant is made of a polyethylene glycol (PEG) material which expands upon contact with subcutaneous fluids to seal the venotomy and is resorbed by the body within 30 days. The MCV VCD is supplied with a 10ml locking syringe used for balloon inflation and deflation. The catheter shaft has a silicone lubricant to facilitate insertion and withdrawal into compatible sheaths. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Rate of patients with same day discharge (SDD) and without subsequent hospitalization/intervention for access-site complications
Tidsram: From time of index procedure through end of following day (within 48 hours)
|
Rate of patients who successfully received a study device at all access sites and had SDD without subsequent hospitalization/intervention for access-site complications either same day post-discharge or the next day |
From time of index procedure through end of following day (within 48 hours)
|
|
Rate of access-site complications
Tidsram: From time of study device introduction at first access site through 14 days post-procedure
|
Rate of access-site complications, assessed per standard of care, through 14 days post-procedure, including:
|
From time of study device introduction at first access site through 14 days post-procedure
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Time to Ambulation
Tidsram: From end of index procedure until time before hospital discharge (usually within ~24 hours of procedure)
|
Defined as elapsed time (in hours) between removal of the final MCV VCD and when subject stands and walks 20 feet without evidence of rebleeding from any femoral venous access site. |
From end of index procedure until time before hospital discharge (usually within ~24 hours of procedure)
|
|
Time to Discharge
Tidsram: From end of index procedure until time of hospital discharge (usually within ~24 hours of procedure)
|
Defined as the elapsed time (in minutes) between removal of the final MCV VCD and when the subject is discharged from the hospital, as recorded on the discharge order. |
From end of index procedure until time of hospital discharge (usually within ~24 hours of procedure)
|
|
Time to Hemostasis
Tidsram: From time of index procedure until time before hospital discharge (usually within ~24 hours of procedure)
|
Defined as elapsed time (in minutes) between removal of each MCV VCD and first observed and confirmed venous hemostasis (per access site analysis). |
From time of index procedure until time before hospital discharge (usually within ~24 hours of procedure)
|
|
SDD sustained MCV VCD success
Tidsram: From end of index procedure through 14 days post-procedure
|
Defined as the proportion of subjects who did not require hospital intervention within 14 days post-procedure due to access site-related complications |
From end of index procedure through 14 days post-procedure
|
|
Device success evaluated at the end of the procedure
Tidsram: End of index procedure
|
Defined as the ability to deploy the delivery system and deliver the PEG component to achieve hemostasis at each access site |
End of index procedure
|
|
Procedural Success
Tidsram: From end of index procedure through 14 days post-procedure
|
Defined as the attainment of final hemostasis at all venous access sites without major venous access site closure-related complications through 14 days |
From end of index procedure through 14 days post-procedure
|
|
Procedural Time
Tidsram: Index procedure
|
Defined as time of first sheath insertion until the time of removal of final MCV VCD. |
Index procedure
|
|
Recovery room time
Tidsram: From time of transfer to recovery room post-discharge to time of discharge (usually within ~24 hours of procedure)
|
Defined as elapsed time (in minutes) between when the subject is transferred to recovery and when the subject is discharged from the hospital, as recorded on the discharge order. |
From time of transfer to recovery room post-discharge to time of discharge (usually within ~24 hours of procedure)
|
|
Analysis of Cost Effectiveness - Comprehensive summary of clinical outcomes, resource utilization, economic proxies, patients reported outcomes and CPT codes
Tidsram: From start time of index procedure through 14 days post-procedure
|
An analysis of cost effectiveness will be performed based on a summary of key clinical outcomes, resource utilization, economic proxies, patients reported outcomes and CPT codes |
From start time of index procedure through 14 days post-procedure
|
|
Incidence of urinary catheter usage
Tidsram: From start time of index procedure through end time of index procedure
|
Number/rate of patients with urinary catheters used during the procedure |
From start time of index procedure through end time of index procedure
|
|
Incidence of protamine usage
Tidsram: From start time of index procedure through end time of index procedure
|
Incidence of protamine usage during the procedure |
From start time of index procedure through end time of index procedure
|
|
Medication Usage
Tidsram: From pre-procedure though study exit/follow-up visit (14 +/- 7 days post-procedure)
|
Rate of patients who are administered anti-platelet, anti-coagulant, anti-thrombotic, local anesthetic, protamine or pain medication |
From pre-procedure though study exit/follow-up visit (14 +/- 7 days post-procedure)
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- P25-8302
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .